University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S94-100. doi: 10.1016/j.bbmt.2010.10.031. Epub 2010 Nov 1.
Minimal residual disease (MRD), both before and after transplantation, is a clinically important yet relatively poorly defined aspect of allogeneic hematopoietic stem cell transplantation (alloHSCT). The clinical relevance of MRD in the context of alloHSCT has been demonstrated by its association with the development of clinical relapse. However, with the possible exception of chronic myeloid leukemia (CML), the specific techniques, timing, frequency, and clinical utility, relative to improvement in patient outcomes, for monitoring MRD in the setting of alloHSCT has yet to be clearly defined. A concise overview of monitoring techniques for detecting MRD, as well as treatment strategies and biological and clinical research initiatives for MRD suggested by the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, is covered in this article.
微小残留病（MRD）无论是在移植前还是移植后，都是异基因造血干细胞移植（alloHSCT）中一个重要但相对定义不明确的方面。MRD 在 alloHSCT 背景下的临床相关性已通过其与临床复发的发展相关得到证明。然而，除慢性髓系白血病（CML）外，监测 alloHSCT 中 MRD 的具体技术、时间、频率和临床实用性，相对于改善患者预后，尚未得到明确界定。本文综述了检测 MRD 的监测技术，以及美国国家癌症研究所首次关于异基因造血干细胞移植后生物学、预防和治疗复发的国际研讨会提出的 MRD 的治疗策略和生物学及临床研究计划。
